Impel Pharmaceuticals Stock Price, News & Analysis

Impel Pharmaceuticals Inc. (symbol: IMPL) is a Seattle-based biopharmaceutical company dedicated to providing groundbreaking therapies for central nervous system (CNS) diseases. Their innovative approach leverages a proprietary nasal drug delivery system known as the POD™ device, which ensures consistent and predictable drug administration to the upper nasal cavity.

Impel's diverse product portfolio is focused on addressing significant unmet medical needs.

• INP104 (POD™ DHE) is in development for the acute treatment of migraine headaches.
• INP103 (POD™ Levodopa) aims to offer relief for Parkinson's disease patients.
• INP105 (POD™ Olanzapine) targets agitation associated with schizophrenia and bipolar disorders.
• INP102 (POD™ Insulin) is being tested in an NIH-funded trial for Alzheimer's disease.

In September 2021, Impel received FDA approval for Trudhesa®, a nasal spray specifically designed for the acute treatment of migraine with or without aura in adults. This marks a significant milestone in their journey to provide effective therapies for CNS conditions.

Despite recent achievements, Impel has encountered financial challenges and has filed for Chapter 11 bankruptcy as part of a strategic decision to maximize value for stakeholders. The company is actively pursuing a sale and has entered into an agreement with JN BIDCO LLC as the 'stalking horse' bidder. Throughout this process, Impel aims to continue operating normally, ensuring minimal disruption to its customers, employees, and other key stakeholders.

For more details, visit Impel Pharmaceuticals Inc.